Rationale and Design of the CREDENCE Trial: computed TomogRaphic evaluation of atherosclerotic DEtermiNants of myocardial IsChEmia

BMC Cardiovascular Disorders

10 Ottobre Ott 2016 2 months ago
  • Andreini D, Pontone G

CREDENCE will determine the performance of integrated Coronary computed tomography angiography (CCTA) metric compared to integrated myocardial perfusion scintigraphy (MPS) measure for diagnosis of vessel-specific ischemia. If proven successful, this study may reduce the number of missed diagnoses and help to optimally predict ischemia-causing lesions.

Reference
Rizvi A, Hartaigh BÓ, Knaapen P, Leipsic J, Shaw LJ, Andreini D, Pontone G, Raman S, Khan MA, Ridner M, Nabi F, Gimelli A, Jang J, Cole J, Nakazato R, Zarins C, Han D, Lee JH, Szymonifika J, Gomez MJ, Truong QA, Chang HJ, Lin FY, Min JK. Rationale and Design of the CREDENCE Trial: computed TomogRaphic evaluation of atherosclerotic DEtermiNants of myocardial IsChEmia. BMC Cardiovasc Disord 2016 Oct 6;16(1):190

Go to PubMed